A Study to Evaluate the Safety and Efficacy of AVTX-002 for the Treatment of Poorly Controlled Non-Eosinophilic Asthma.

Summary

The primary objective of this study is to evaluate the efficacy of AVTX-002 compared with placebo in patients with poorly controlled non-eosinophilic asthma (NEA).

Timeline

Start

2022-02-24

Primary completion

2023-05-11

Completion

2023-05-11

Outcome

Missed primary endpoint

release “AVTX-002 did not meet the primary endpoint measured by reduction in asthma related events compared to placebo” avalotx.com ↗

Drugs

Indications